Oppenheimer analyst Jay Olson maintained a Buy rating on Biogen (NASDAQ:BIIB) on Wednesday, setting a price target of $300, which is approximately 10.43% above the present share price of $271.67.
Olson expects Biogen to post earnings per share (EPS) of $4.47 for the first quarter of 2021.
The current consensus among 24 TipRanks analysts is for a Hold rating of shares in Biogen, with an average price target of $294.32.
The analysts price targets range from a high of $450 to a low of $175.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $3.38 billion and a net profit of $1.06 billion. The company's market cap is $41.81 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.5% and a 51.10% success rate.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp (OTC:SHCAY) in 1978 and is headquartered in Cambridge, MA.